TY - JOUR
T1 - Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes
AU - Tobin, W. Oliver
AU - Kalinowska-Lyszczarz, Alicja
AU - Weigand, Stephen D.
AU - Guo, Yong
AU - Tosakulwong, Nirubol
AU - Parisi, Joseph E.
AU - Metz, Imke
AU - Frischer, Josa M.
AU - Lassmann, Hans
AU - Brück, Wolfgang
AU - Linbo, Linda
AU - Lucchinetti, Claudia F.
N1 - Funding Information:
W. O. Tobin receives research funding from the Mayo Clinic Center for MS and Autoimmune Neurology. A. Kalinowska-Lyszczarz, S. Weigand, Y. Guo, N. Tosakulwong, J. Parisi, and I. Metz report no disclosures relevant to this manuscript. J. Frischer was supported by the Austrian Science Fund (FWF Project J3508-B24) while conducting parts of this work. H. Lassmann, W. Brück, L. Linbo, and C. Lucchinetti report no disclosures relevant to this manuscript. Go to Neurology.org/N for full disclosures.
Funding Information:
This study was funded by Novartis (CFTY720DUS37T) and the NIH (R01NS49577-7). J.M.F. was supported by the Austrian Science Fund (FWF Project J3508-B24) while conducting parts of this work. W.O.T. receives research funding from the Mayo Clinic Center for MS and Autoimmune Neurology.
Publisher Copyright:
© American Academy of Neurology.
PY - 2021/11/9
Y1 - 2021/11/9
N2 - Background and ObjectivesThe goal of this work was to compare clinical characteristics across immunopathologic subtypes of patients with multiple sclerosis.MethodsImmunopathologic subtyping was performed on specimens from 547 patients with biopsy- or autopsy-confirmed CNS demyelination.ResultsThe frequency of immunopathologic subtypes was 23% for pattern I, 56% for pattern II, and 22% for pattern III. Immunopatterns were similar in terms of age at autopsy/biopsy median age 41 years, range 4-83 years, p = 0.16 and proportion female 54%, p = 0.71. Median follow-up after symptom onset was 2.3 years range 0-38 years. In addition to being overrepresented among autopsy cases 45% vs 19% in biopsy cohort, p < 0.001, index attack-related disability was higher in pattern III vs II median Expanded Disability Status Scale score 4 vs 3, p = 0.02. Monophasic clinical course was more common in patients with pattern III than pattern I or II 59% vs 33% vs 32%, p < 0.001. Similarly, patients with pattern III pathology were likely to have progressive disease compared to patients with patterns I or II when followed up for ≥5 years 24% overall, p = 0.49, with no differences in long-term survival, despite a more fulminant attack presentation.ConclusionAll 3 immunopatterns can be detected in active lesions, although they are found less frequently later into the disease due to the lower number of active lesions. Pattern III is associated with a more fulminant initial attack than either pattern I or II. Biopsied patients appear to have similar long-term outcomes regardless of their immunopatterns. Progressive disease is less associated with the initial immunopattern and suggests convergence into a final common pathway related to the chronically denuded axon.
AB - Background and ObjectivesThe goal of this work was to compare clinical characteristics across immunopathologic subtypes of patients with multiple sclerosis.MethodsImmunopathologic subtyping was performed on specimens from 547 patients with biopsy- or autopsy-confirmed CNS demyelination.ResultsThe frequency of immunopathologic subtypes was 23% for pattern I, 56% for pattern II, and 22% for pattern III. Immunopatterns were similar in terms of age at autopsy/biopsy median age 41 years, range 4-83 years, p = 0.16 and proportion female 54%, p = 0.71. Median follow-up after symptom onset was 2.3 years range 0-38 years. In addition to being overrepresented among autopsy cases 45% vs 19% in biopsy cohort, p < 0.001, index attack-related disability was higher in pattern III vs II median Expanded Disability Status Scale score 4 vs 3, p = 0.02. Monophasic clinical course was more common in patients with pattern III than pattern I or II 59% vs 33% vs 32%, p < 0.001. Similarly, patients with pattern III pathology were likely to have progressive disease compared to patients with patterns I or II when followed up for ≥5 years 24% overall, p = 0.49, with no differences in long-term survival, despite a more fulminant attack presentation.ConclusionAll 3 immunopatterns can be detected in active lesions, although they are found less frequently later into the disease due to the lower number of active lesions. Pattern III is associated with a more fulminant initial attack than either pattern I or II. Biopsied patients appear to have similar long-term outcomes regardless of their immunopatterns. Progressive disease is less associated with the initial immunopattern and suggests convergence into a final common pathway related to the chronically denuded axon.
UR - http://www.scopus.com/inward/record.url?scp=85120778687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120778687&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000012782
DO - 10.1212/WNL.0000000000012782
M3 - Article
C2 - 34504026
AN - SCOPUS:85120778687
SN - 0028-3878
VL - 97
SP - E1906-E1913
JO - Neurology
JF - Neurology
IS - 19
ER -